Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
BDSX 
Biodesix Inc (BDSX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/04/2025: BDSX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
6 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $32.5
1 Year Target Price $32.5
| 4 | Strong Buy |
| 1 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -66.58% | Avg. Invested days 25 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/04/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 68.32M USD | Price to earnings Ratio - | 1Y Target Price 32.5 |
Price to earnings Ratio - | 1Y Target Price 32.5 | ||
Volume (30-day avg) 6 | Beta 0.64 | 52 Weeks Range 3.44 - 32.20 | Updated Date 12/5/2025 |
52 Weeks Range 3.44 - 32.20 | Updated Date 12/5/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -5.34 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -49.31% | Operating Margin (TTM) -32.36% |
Management Effectiveness
Return on Assets (TTM) -21.12% | Return on Equity (TTM) -302.55% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 119770587 | Price to Sales(TTM) 0.85 |
Enterprise Value 119770587 | Price to Sales(TTM) 0.85 | ||
Enterprise Value to Revenue 1.48 | Enterprise Value to EBITDA -2.72 | Shares Outstanding 7955685 | Shares Floating 3388167 |
Shares Outstanding 7955685 | Shares Floating 3388167 | ||
Percent Insiders 52.26 | Percent Institutions 18.08 |
Upturn AI SWOT
Biodesix Inc
Company Overview
History and Background
Biodesix, Inc. (BDSX) was founded in 2005 and is based in Boulder, Colorado. It is a data-driven diagnostic solutions company addressing unmet needs in lung disease. It focuses on developing and commercializing diagnostic tests to improve patient outcomes.
Core Business Areas
- Lung Diagnostic Tests: Offers a range of diagnostic tests for lung nodules, lung cancer diagnosis, and monitoring of lung disease progression. Tests leverage proteomics and genomics to provide clinically actionable information.
Leadership and Structure
The leadership team includes Scott Hutton (CEO), Robin Garner (CFO), and others in key roles. The organizational structure includes departments for research and development, commercial operations, and finance.
Top Products and Market Share
Key Offerings
- Competitors: VCYT,EXAS
- Nodify Lung Nodule Risk Assessment: A blood-based test to assess the risk of malignancy in lung nodules. Competitors: Veracyte (VCYT), Exact Sciences (EXAS). Market share data is not easily accessible. Revenue generated is partially reported and combined with other services.
- Competitors: ROCH,GH
- LungStrat CDx Dx: A blood-based diagnostic test designed to improve the selection of first-line treatment options for patients with advanced non-small cell lung cancer. Competitors include Foundation Medicine (ROCH) (subsidiary of Roche), Guardant Health (GH). Market share data is not easily accessible. Revenue generated is partially reported and combined with other services.
Market Dynamics
Industry Overview
The diagnostic testing industry is experiencing growth, driven by advancements in technology, increasing prevalence of chronic diseases, and a focus on personalized medicine. There is high competition and a growing need for precise diagnostic tools.
Positioning
Biodesix aims to be a key player in the lung disease diagnostics market by providing differentiated tests that improve patient outcomes. Its competitive advantage lies in its multi-omic approach and data-driven insights.
Total Addressable Market (TAM)
The TAM for lung cancer diagnostics is estimated to be in the billions of dollars. Biodesix is positioned to capture a portion of this market by offering clinically relevant and cost-effective tests.
Upturn SWOT Analysis
Strengths
- Proprietary diagnostic platforms
- Focus on unmet needs in lung disease
- Strong clinical validation data
- Experienced management team
Weaknesses
- Limited commercial infrastructure
- Dependence on reimbursement approvals
- High cash burn rate
- Competition from larger players
Opportunities
- Expansion into new geographic markets
- Development of new diagnostic tests
- Partnerships with pharmaceutical companies
- Increasing adoption of personalized medicine
Threats
- Regulatory changes
- Pricing pressure from payers
- Technological advancements by competitors
- Economic downturn
Competitors and Market Share
Key Competitors
- VCYT
- EXAS
- GH
- ROCH
Competitive Landscape
Biodesix is a smaller player compared to its competitors. It has a differentiated product portfolio and a focus on lung disease diagnostics, but faces challenges in terms of commercial reach and financial resources.
Growth Trajectory and Initiatives
Historical Growth: Biodesix has demonstrated revenue growth. However, this growth has not yet translated into profitability.
Future Projections: Analysts project revenue to continue growing, driven by increased adoption of the company's diagnostic tests. Projections are contingent on securing reimbursement approvals and achieving profitability.
Recent Initiatives: Recent initiatives include expanding the commercial team, launching new diagnostic tests, and pursuing strategic partnerships.
Summary
Biodesix is a diagnostic company specializing in lung diseases with growing revenues. It is not yet profitable and faces strong competition from larger companies. Their financial sustainability depends on securing reimbursement and improving cash flow.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company Filings
- Analyst Reports
- Industry Publications
Disclaimers:
The information provided is for informational purposes only and does not constitute investment advice. Market share data is based on available estimates and may not be precise. Financial data and projections are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Biodesix Inc
Exchange NASDAQ | Headquaters Louisville, CO, United States | ||
IPO Launch date 2020-10-28 | President, CEO & Director Mr. Scott Hutton | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 273 | Website https://www.biodesix.com |
Full time employees 273 | Website https://www.biodesix.com | ||
Biodesix, Inc. operates as a diagnostic solutions company. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests markets as Nodify Lung Nodule Risk Assessment testing to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also provides GeneStrat ddPCR, GeneStrat NGS, and VeriStrat tests markets as part of IQLung testing strategy, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to guide treatment decisions. In addition, the company provides diagnostic solutions, including translational research, initial biomarker discovery, assay design, development, and validation, testing of clinical trial samples, regulatory, reimbursement, commercialization, and logistical support services for biopharmaceutical, life sciences, and diagnostic companies. The company was formerly known as Elston Technologies, Inc. and as changed to Biodesix, Inc. in 2006. Biodesix, Inc. was incorporated in 2005 and is headquartered in Louisville, Colorado.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.